TTK Healthcare Limited (TTKHLTCARE.NS)
INR 1210.8
(1.63%)
INR 1210.8
(1.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 999.34 Million INR | -53.22% |
| 2022 | 796.8 Million INR | 104.67% |
| 2021 | 406.58 Million INR | -13.71% |
| 2020 | 373.52 Million INR | 18.71% |
| 2019 | 370.7 Million INR | -34.87% |
| 2018 | 573.07 Million INR | 15.11% |
| 2017 | 501.18 Million INR | 14.47% |
| 2016 | 442.08 Million INR | -4.11% |
| 2015 | 460.61 Million INR | 25.71% |
| 2014 | 361.16 Million INR | 38.03% |
| 2013 | 258.27 Million INR | 1.64% |
| 2012 | 268.85 Million INR | -8.18% |
| 2011 | 284.65 Million INR | 18.44% |
| 2010 | 258.37 Million INR | 39.23% |
| 2009 | 173.2 Million INR | 14.54% |
| 2008 | 151.21 Million INR | -39.51% |
| 2007 | 249.97 Million INR | 172.82% |
| 2006 | 91.62 Million INR | 13.69% |
| 2005 | 80.59 Million INR | 1635.1% |
| 2004 | 4.64 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 69.06 Million INR | 53.48% |
| 2024 Q2 | 259.3 Million INR | -40.67% |
| 2023 Q4 | 124.17 Million INR | -41.54% |
| 2023 Q3 | 212.39 Million INR | -16.92% |
| 2023 FY | - INR | -53.22% |
| 2023 Q1 | 246.54 Million INR | -19.92% |
| 2023 Q2 | 255.65 Million INR | 3.69% |
| 2022 Q2 | 150.52 Million INR | 10.5% |
| 2022 Q4 | 307.88 Million INR | 52.28% |
| 2022 FY | - INR | 104.67% |
| 2022 Q1 | 136.21 Million INR | 194.02% |
| 2022 Q3 | 202.18 Million INR | 34.31% |
| 2021 Q2 | 188.21 Million INR | 51.02% |
| 2021 Q1 | 124.62 Million INR | -30.7% |
| 2021 Q3 | 215.83 Million INR | 14.68% |
| 2021 FY | - INR | -13.71% |
| 2021 Q4 | -144.88 Million INR | -167.12% |
| 2020 Q4 | 179.84 Million INR | 25.37% |
| 2020 Q2 | 111.99 Million INR | 803.36% |
| 2020 FY | - INR | 18.71% |
| 2020 Q1 | 12.39 Million INR | -80.8% |
| 2020 Q3 | 143.44 Million INR | 28.08% |
| 2019 Q3 | 109.26 Million INR | 5.38% |
| 2019 FY | - INR | -34.87% |
| 2019 Q4 | 64.55 Million INR | -40.91% |
| 2019 Q2 | 103.67 Million INR | 0.56% |
| 2019 Q1 | 103.1 Million INR | -22.03% |
| 2018 Q4 | 132.22 Million INR | 8.46% |
| 2018 FY | - INR | 15.11% |
| 2018 Q3 | 121.91 Million INR | -20.76% |
| 2018 Q2 | 153.84 Million INR | -12.8% |
| 2018 Q1 | 176.42 Million INR | -3.28% |
| 2017 Q3 | 208.96 Million INR | 45.42% |
| 2017 Q4 | 182.41 Million INR | -12.7% |
| 2017 FY | - INR | 14.47% |
| 2017 Q1 | -8.11 Million INR | -107.51% |
| 2017 Q2 | 143.69 Million INR | 1870.33% |
| 2016 Q3 | 92.85 Million INR | -16.27% |
| 2016 Q4 | 108.07 Million INR | 16.38% |
| 2016 Q1 | 130.25 Million INR | 4.95% |
| 2016 Q2 | 110.89 Million INR | -14.86% |
| 2016 FY | - INR | -4.11% |
| 2015 Q2 | 100.95 Million INR | 1.44% |
| 2015 Q4 | 124.11 Million INR | -9.99% |
| 2015 FY | - INR | 25.71% |
| 2015 Q1 | 99.53 Million INR | -14.92% |
| 2015 Q3 | 137.88 Million INR | 36.57% |
| 2014 Q1 | 77.79 Million INR | -1.87% |
| 2014 FY | - INR | 38.03% |
| 2014 Q4 | 116.98 Million INR | 27.54% |
| 2014 Q3 | 91.72 Million INR | 12.68% |
| 2014 Q2 | 81.4 Million INR | 4.65% |
| 2013 Q4 | 79.27 Million INR | 13.49% |
| 2013 FY | - INR | 1.64% |
| 2013 Q3 | 69.85 Million INR | -1.37% |
| 2013 Q2 | 70.82 Million INR | 304.84% |
| 2013 Q1 | 17.49 Million INR | -60.98% |
| 2012 FY | - INR | -8.18% |
| 2012 Q2 | 74.23 Million INR | 23.4% |
| 2012 Q1 | 60.15 Million INR | -14.1% |
| 2012 Q4 | 44.84 Million INR | -24.28% |
| 2012 Q3 | 59.21 Million INR | -20.23% |
| 2011 Q4 | 70.02 Million INR | -4.79% |
| 2011 Q3 | 73.55 Million INR | 0.0% |
| 2011 FY | - INR | 18.44% |
| 2010 FY | - INR | 39.23% |
| 2009 FY | - INR | 14.54% |
| 2008 FY | - INR | -39.51% |
| 2007 FY | - INR | 172.82% |
| 2006 FY | - INR | 13.69% |
| 2005 FY | - INR | 1635.1% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott India Limited | 16.97 Billion INR | 94.114% |
| Cipla Limited | 67.19 Billion INR | 98.513% |
| Gland Pharma Limited | 13.33 Billion INR | 92.503% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | 88.737% |
| Kopran Limited | 744.13 Million INR | -34.296% |
| Marksans Pharma Limited | 4.58 Billion INR | 78.208% |
| NGL Fine-Chem Limited | 678.68 Million INR | -47.247% |
| Pfizer Limited | 8.23 Billion INR | 87.869% |
| Sanofi India Limited | 8.86 Billion INR | 88.731% |
| SMS Pharmaceuticals Limited | 1.21 Billion INR | 17.464% |